SCHEMBL4384693

SCHEMBL4384693

Cc1cc(O)cc(=O)n1-c1cc(C(=O)O)cc(C(=O)O)c1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR4A1 P22736 2/20 0.59
POLB P06746 5/20 0.53
KDM4E B2RXH2 4/20 0.53
L3MBTL1 Q9Y468 3/20 0.53
CTDSP1 Q9GZU7 2/20 0.53
HTT P42858 1/20 0.53
CASP6 P55212 1/20 0.53
HCAR1 Q9BXC0 2/20 0.46
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
KMT2A Q03164 4/20 0.42
TDP1 Q9NUW8 4/20 0.42
ALDH1A1 P00352 3/20 0.42
MAPT P10636 3/20 0.42
MYC P01106 3/20 0.42
MEN1 O00255 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4384906 0.83 ALDH1A1 (0.56) NR4A1POLBKDM4EL3MBTL1HTT
SCHEMBL4382040 0.76 NR4A1 (0.54) NR4A1POLBKDM4EL3MBTL1CTDSP1
SCHEMBL12798353 0.75 ALDH1A1 (0.57) POLBKDM4EL3MBTL1KMT2ATDP1
SCHEMBL4375887 0.75 MYC (0.65) POLBKDM4EL3MBTL1KMT2ATDP1
SCHEMBL2831953 0.74 NR4A1 (1.00) NR4A1POLBKDM4EL3MBTL1CTDSP1
SCHEMBL6504363 0.74 MYC (0.41) POLBKDM4ECA12CA1CA2
SCHEMBL4377003 0.72 ALDH1A1 (0.53) POLBKDM4EHTTCA12CA1
SCHEMBL4377764 0.69 ALDH1A1 (0.52) POLBL3MBTL1CA12CA1CA2
Phloroglucinol SCHEMBL21465836 0.69 CA12 (0.88) POLBKDM4EL3MBTL1HCAR1CA12
SCHEMBL139644 0.69 CA12 (0.88) POLBKDM4EL3MBTL1HCAR1CA12

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7629363-B2 antiinflammatory agent for treating asthma and chronic pulmonary inflammatory disease PFIZER INC (US) 2009-12-08 US disclosed
EP-1490064-B1 SUBSTITUTED PYRIDINONES AS MODULATORS OF P38 MAP KINASE PHARMACIA CORP (US) 2009-11-18 EP disclosed
US-7067540-B2 Substituted pyridinones PHARMACIA CORPORATION (US) 2006-06-27 US disclosed
US-20050176775-A1 Substituted pyridinones PHARMACIA CORPORATION 2005-08-11 US disclosed
US-20040058964-A1 Substituted pyridinones PHARMACIA LLC 2004-03-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058964-A1 Substituted pyridinones MAPK1, MAPK6, MAPK7 NR4A1 1629/4885POLB 1610/4885KDM4E 3869/4885
US-20050176775-A1 Substituted pyridinones MAPK1, MAPK6, MAP3K6 NR4A1 1760/4885POLB 1676/4885KDM4E 3921/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.